The summit brought together some of the most innovative researchers, clinicians and funders serving the FLC community, including Johns Hopkins, Rush University, University of Maryland, along with co-hosts St. Jude Children’s Research Hospital and U of Tennessee and The Fibrolamellar Cancer Foundation.
The meeting highlighted many of the latest discoveries in FLC immunotherapy which were shared confidentially amongst this distinguished group, raising much hope for new therapeutic approaches. FCF President John Hopper and Scientific Director Dr Mark Furth foresee significant ongoing collaboration with these partners in 2019/2020 .
This new and exciting collaboration increases the importance of access to bio-specimen material. Patients can play a major role in accelerating this research by participating in FCF’s bio-specimen collection program coordinated by Tom Stockwell. FCF offers multiple options for tissue donation, details of which can be found here. Please help these innovative researchers take the next steps in searching to control and cure fibrolamellar.